Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Neurofilament light, a biomarker elevated in neurodegeneration and dementia, was higher among poor sleepers with Pittsburgh Sleep Quality Index scores of less than 5.

Poor Sleep Quality Correlated With Higher Neurofilament Light Levels in Veterans

Videos

At CMSC 2023, the associate professor of neurological sciences at the University of Vermont in Burlington talked about data surrounding multiple sclerosis diagnosis and misdiagnosis, suggesting the need for the development of diagnostic biomarkers. [WATCH TIME: 5 minutes] 

Challenges and Advancements in Biomarkers for Accurate Diagnosis in MS: Andrew Solomon, MD

At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]

Rethinking MS as a Smoldering Disease and the Role of the Epstein Barr Virus: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath

Most patients completed at least 3 years of treatment, with no new safety signals observed and a treatment discontinuation rate of 5.3%.

Positive Long-Term Safety, Low Discontinuation Rates Seen With Vidofludimus Calcium

Associate professor of neurological sciences and chief of the Multiple Sclerosis Division at the University of Vermont in Burlington.

Speech-Language Pathologist, Orlando Health.

At CMSC 2023, the neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed the importance of early intervention in speech and communication therapy, as well as the challenges faced in getting patients to seek therapy at the time of diagnosis. [WATCH TIME: 5 minutes] 

Overcoming Challenges and Early Intervention for Speech Therapy in MS: Rachel Haines, MA, CCC-SLP, MSCS, CBIS

, has been with the team since October 2019. Follow him on Twitter 

With few neuropalliative care services available in the US, the University of Rochester stands as a prime example of how a successful program can transform patient care. 

Leading by Example: How the University of Rochester’s Neuropalliative Care Service Expands Treatment Possibilities

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

CMSC 2023

NMOSD

Narcolepsy

Parkinson Disease

SLEEP 2023

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

Therapies in Development for Acute Migraine

Ubrogepant: Treatment for Acute Migraine

Rimegepant: Treatment for Acute Migraine

Patient Selection for Acute Migraine Therapy

Acute Migraine Treatment Goals

Treatment Goals for Acute Migraine

Treating Acute Migraine in the Community Setting

Acute Migraine Treatment: What’s Next?

Real-World Experience With Gepants for Acute Migraine

Gepants for Acute Migraine: Patient Management

Gepants for Acute Migraine: Safety & Efficacy Data

 Advances in the Treatment of Acute Migraine

Burden of Migraine

With approximately 500 board-certified headache specialists and just over 60 million Americans with headache, the average wait time to see one of us is 3 to 4 months. Technology may hold the key to issues such as this.

Welcome Inside the Box, Circa 1990!

Robert Cowan, MD

Articles